Clinical Evaluation of a New Automated Anti-dsDNA Fluorescent Immunoassay

Hernando, Monserrat; González, C.; Sánchez, Angel; Guevara, Paloma; Navajo, José Alejandro; Papisch, Wolfgang; González-Buitrago, José Manuel

doi:10.1515/cclm.2002.185

Cited by 31 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our analysis demonstrates that the other test systems performed comparably to the Farr RIA and, therefore, may represent easier-to-use alternatives for routine practice. In particular, the specificity of the EliA system for the diagnosis of SLE was comparable to that of the Farr RIA, in agreement with the studies of Hernando et al (8 ) and Villalta et al (9 ). The authors of the latter studies proposed the EliA system as a substitute for the Farr RIA, but their recommendations were not based on ROC analysis.…”

supporting

confidence: 86%

“…It is known that regardless of International Federation of Gynecology and Obstetrics (FIGO) stage, positive peritoneal washing cytology predicts poor prognosis for women with epithelial tumors of the genital tract, except for patients with borderline ovarian tumors (4 ). Because of the diagnostic pitfalls entailed in the cytologic examination of peritoneal washings (5 ), some additional methods for peritoneal fluid diagnosis have been tested, including flow cytometric DNA analysis (6 ) and a telomerase assay (7,8 ).…”

mentioning

confidence: 99%

See 1 more Smart Citation

ROC Analysis Comparison of Three Assays for the Detection of Antibodies against Double-Stranded DNA in Serum for the Diagnosis of Systemic Lupus Erythematosus

et al. 2004

View full text Add to dashboard Cite

supporting

confidence: 86%

mentioning

confidence: 99%

ROC Analysis Comparison of Three Assays for the Detection of Antibodies against Double-Stranded DNA in Serum for the Diagnosis of Systemic Lupus Erythematosus

et al. 2004

View full text Add to dashboard Cite

“…On the other hand, such information is not always requested and may confuse the clinical interpretation of laboratory results. Recent studies comparing anti-dsDNA assays reveal an outstanding SLE specificity of CLIFT, but various results when it comes to sensitivity and ability to mirror or predict disease activity [133,211,212]. Further evaluation of anti-dsDNA methods may discern promising assays detecting anti-dsDNA of clinical importance.…”

Section: Discussion About Anti-dsdna Assaysmentioning

confidence: 99%

Biomarkers and mediators in systemic lupus erythematosus : IFNα versus the CRP response, and evaluation of suPAR and anti-dsDNA antibody assays

Enocsson¹

2014

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease which may affect multiple organ systems. Interferon alpha (IFNα) and autoantibodies that form immune complexes with nuclear antigens (ANA) are hallmarks believed to drive the disease into a vicious circle of inflammation, tissue damage, autoantigen exposure and autoantibody production.In SLE, the disease course is characterized by episodes of exacerbations alternating with remissions. In order to best treat the patient it is important to closely monitor symptoms and signs of disease activity. Because of the disease heterogeneity, no single biomarker has yet been found to reflect SLE disease activity in general, although anti-double stranded DNA (anti-dsDNA) antibodies sometimes indicate activity, primarily with renal involvement, and constitutes an item of the SLE disease activity score SLEDAI-2K. However, the method of anti-dsDNA measurement is not standardized and therefore varies between different laboratories. In many other inflammatory conditions, such as rheumatoid arthritis and during bacterial infections, the C-reactive protein (CRP) level is a good indicator of ongoing inflammation, but in SLE and during viral infections, CRP commonly fails to reflect the degree of inflammation. Both viral infections and SLE are characterized by IFNα, and we thus aimed to elucidate whether IFNα can inhibit CRP production. Further, four assays for anti-dsDNA antibody measurements were evaluated with regard to SLE disease specificity and activity, and a new potential biomarker of inflammation, the soluble urokinase plasminogen activator receptor (suPAR), was assessed in relation to disease activity and organ damage.An in vitro inhibitory effect of IFNα on CRP transcription and production was found in hepatocytes, and this was consolidated by in vivo studies of CRP and IFNα in sera from well-characterized SLE patients (KLURING; Kliniskt lupusregister i nordöstra Götaland). Here, CRP and disease activity were associated among patients without IFNα and without a CRP lowering gene variant (SNP rs1205). The poor disease activity compliance of CRP could therefore be explained, at least in part, by polymorphisms in the CRP gene and increased levels of IFNα. Critical differences between the methods measuring anti-dsDNA were found regarding disease specificity and ability to reflect disease activity and the results suggests the Crithidia luciliae immunofluorescence test (CLIFT) for diagnostic purposes and a bead-based multiplex assay (FIDIS) for monitoring of disease activity.

show abstract

“…Second, the Farr radioimmunoassay is often the standard by which all other methods of anti-dsDNA antibodies detection in SLE are judged (2). Farr is quantitative, with results that can be expressed in IU/ml, measures high avidity antibodies, and is considered specific for SLE when high quality, radiolabeled, procariotic DNA is used (2)(3)(4). It has its drawbacks (5): cannot be automated and is the most labor intensive.…”

Section: Introductionmentioning

confidence: 99%

Myth and reality: practical test system for the measurement of anti‐DNA antibodies in the diagnosis of systemic lupus erythematosus (SLE)

McCloskey

Christner

Jacobs-Kosmin

et al. 2010

Clinical Laboratory Analysis

View full text Add to dashboard Cite

The myth persists that only the labor intensive Farr radioimmunoassay and Crithidia luciliae immunofluorescence (CL-IFA) are systemic lupus erythematosus (SLE)-specific tests. We compared them to ELISA with bacteriophage lambda DNA (EL-dsDNA) and denatured calf thymus DNA (EL-ssDNA). By percentile ranking, the specificity cut-off level was set both out of clinical context (SOCC) on 100 blood bank donors, and in clinical context (SICC) on 100 patients with either rheumatoid arthritis or scleroderma (50/50). Clinical sensitivity was calculated on 100 random SLE patients. At 95% SICC, the sensitivity of Farr, CL-IFA, EL-dsDNA, and EL-ssDNA was similar (95%CI): 76% (66-84), 76% (66-84), 63% (53-72), and 75% (65-83), respectively; 87% of the patients were positive by at least one method and 55%by all methods. At 99% SICC, the sensitivity was also similar (95% CI): 57% (47-67), 47% (37-57), 58% (47-67), and 43% (33-53), respectively. The areas under ROC curve were similar (95% CI) when patients were used as controls for specificity. At 99% SOCC, EL-ssDNA identified 89% positive, 2 negative but positive by another method at 95% SICC, and 9 negative (i.e. 89/2/9), followed by CL-IFA (80/6/14), Farr (76/12/12), and EL-dsDNA (64/23/13). Thus, at relatively low cost and easy automation, under the same conditions of specificity, the two ELISA tests combined were at least as good, if not superior, to CL-IFA or Farr: they showed similar clinical sensitivity and also identified more patients with anti-DNA antibodies.

show abstract

Clinical Evaluation of a New Automated Anti-dsDNA Fluorescent Immunoassay

Cited by 31 publications

References 15 publications

ROC Analysis Comparison of Three Assays for the Detection of Antibodies against Double-Stranded DNA in Serum for the Diagnosis of Systemic Lupus Erythematosus

ROC Analysis Comparison of Three Assays for the Detection of Antibodies against Double-Stranded DNA in Serum for the Diagnosis of Systemic Lupus Erythematosus

Biomarkers and mediators in systemic lupus erythematosus : IFNα versus the CRP response, and evaluation of suPAR and anti-dsDNA antibody assays

Myth and reality: practical test system for the measurement of anti‐DNA antibodies in the diagnosis of systemic lupus erythematosus (SLE)

Contact Info

Product

Resources

About